Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Conditions
Interventions
Tinengotinib 8 mg
Tinengotinib 10 mg
+1 more
Locations
87
United States
UCLA Medical Center
Santa Monica, California, United States
Stanford Cancer Center
Stanford, California, United States
The University of Kansas Cancer Center
Westwood, Los Angeles, California, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
The University of Chicago Hospitals
Chicago, Illinois, United States
UMass Memorial Medical Center
Worcester, Massachusetts, United States
Start Date
December 20, 2023
Primary Completion Date
May 1, 2026
Completion Date
August 1, 2026
Last Updated
June 24, 2024
NCT05969860
NCT06503146
NCT07486713
NCT07282912
NCT07146646
NCT04753996
Lead Sponsor
TransThera Sciences (Nanjing), Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions